Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-18626

Hemmatazad, H; Maciejewska Rodrigues, H; Maurer, B; Brentano, F; Pileckyte, M; Distler, J H W; Gay, R E; Michel, B A; Gay, S; Huber, L C; Distler, O; Jüngel, A (2009). Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis and Rheumatism, 60(5):1519-1529.

[img]
Preview
Accepted Version
PDF
171kB

View at publisher
[img]
Preview
PDF
209kB

Abstract

OBJECTIVE: We have recently shown a significant reduction in cytokine-induced transcription of type I collagen and fibronectin in systemic sclerosis (SSc) skin fibroblasts upon treatment with trichostatin A (TSA). Moreover, in a mouse model of fibrosis, TSA prevented the dermal accumulation of extracellular matrix. The purpose of this study was to analyze the silencing of histone deacetylase 7 (HDAC-7) as a possible mechanism by which TSA exerts its antifibrotic function. METHODS: Skin fibroblasts from patients with SSc were treated with TSA and/or transforming growth factor beta. Expression of HDACs 1-11, extracellular matrix proteins, connective tissue growth factor (CTGF), and intercellular adhesion molecule 1 (ICAM-1) was analyzed by real-time polymerase chain reaction, Western blotting, and the Sircol collagen assay. HDAC-7 was silenced using small interfering RNA. RESULTS: SSc fibroblasts did not show a specific pattern of expression of HDACs. TSA significantly inhibited the expression of HDAC-7, whereas HDAC-3 was up-regulated. Silencing of HDAC-7 decreased the constitutive and cytokine-induced production of type I and type III collagen, but not fibronectin, as TSA had done. Most interestingly, TSA induced the expression of CTGF and ICAM-1, while silencing of HDAC-7 had no effect on their expression. CONCLUSION: Silencing of HDAC-7 appears to be not only as effective as TSA, but also a more specific target for the treatment of SSc, because it does not up-regulate the expression of profibrotic molecules such as ICAM-1 and CTGF. This observation may lead to the development of more specific and less toxic targeted therapies for SSc.

Citations

27 citations in Web of Science®
30 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

81 downloads since deposited on 25 May 2009
26 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Center for Integrative Human Physiology
04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
DDC:570 Life sciences; biology
610 Medicine & health
Language:English
Date:May 2009
Deposited On:25 May 2009 04:48
Last Modified:21 Jun 2014 19:17
Publisher:Wiley-Blackwell
ISSN:0004-3591
Additional Information:The attached file is a preprint (accepted version) of an article published in http://www3.interscience.wiley.com/journal/76509746/home?CRETRY=1&SRETRY=0
Publisher DOI:10.1002/art.24494
PubMed ID:19404935

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page